<DOC>
	<DOCNO>NCT00239473</DOCNO>
	<brief_summary>The primary objective compare bronchodilator efficacy two dos ( 5 mcg 10 mcg ) tiotropium inhalation solution deliver Respimat inhaler daily placebo ipratropium bromide MDI four time daily patient COPD . The secondary objective compare safety tiotropium inhalation solution deliver Respimat placebo ipratropium bromide MDI .</brief_summary>
	<brief_title>12 Week Comparison 5 Mcg 10 Mcg Tiotropium / Respimat , Placebo Ipratropium MDI COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Outpatients either sex , age &gt; /= 40 year diagnosis COPD ( FEV1 &lt; /= 60 % predict [ ECCS criterion ] FEV1/FVC &lt; /= 70 % )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>